The annual list showcases companies making a difference to combat global issues and drive positive social or environmental change, Medtronic says.
Medtronic received recognition for its Symplicity procedure, which utilizes the Symplicity Spyral renal denervation (RDN) system. Symplicity Spyral delivers radiofrequency energy to nerves near kidneys in a minimally invasive procedure. These nerves can become overactive and contribute to high blood pressure.
In the procedure, after sedation, a doctor inserts a thin tube into the artery leading to the kidney. The doctor then administers energy to calm the excessive activity of the nerves connected to the kidney. Then, the tube is removed, leaving no implant behind.
The RDN system holds approval for commercial use in more than 75 countries. Medtronic received a landmark approval for the system in November 2023. Approval made Medtronic the second company with such approval, following Recor Medical’s nod earlier that month.
“It’s an honor to have the Symplicity blood pressure procedure recognized with such a prestigious award,” said Jason Weidman, SVP and president of the Coronary and Renal Denervation business at Medtronic. “High blood pressure is a global health epidemic, and the introduction of the Symplicity blood pressure procedure is a testament to what Medtronic does best – we work with our clinical community to solve large health challenges by bringing together science, engineering, and technology to improve patients’ lives. This award is truly a culmination of everyone’s hard work.”
(See Weidman speak at DeviceTalks West, Oct. 16–17, 2024 in Santa Clara, California.)
